Novo Nordisk CEO to Testify on High US Drug Prices

Lars Fruergaard Jørgensen will address the Senate on the disparity in costs for diabetes and weight-loss medications in September.

Senator Bernie Sanders canceled a subpoena vote after the CEO agreed to testify voluntarily.
Novo Nordisk's Ozempic and Wegovy are significantly more expensive in the US compared to other countries.
The Senate committee's investigation revealed potential financial strain on the US healthcare system due to high drug prices.
Novo Nordisk attributes the price disparity to the complex US healthcare system and intermediary costs.
The company's profits surged amid rising demand for its GLP-1 drugs, despite criticism over pricing.